Contineum Therapeutics reported cash from operations of -$11.50M and free cash flow of -$11.51M for the quarter ended Jun 2026, up 26.6% year over year. This cash flow statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Net Income | -4.82M | 41.57M | -6.25M | -12.21M | -8.42M | -9.01M | -10.27M | -5.68M | -18.01M | -15.87M | -12.97M | -15.11M | -17.42M | -15.09M |
| Share-based Compensation | 0.01M | 0.01M | 0.00M | 0.76M | 9.20M | 24.10M | 4.12M | 2.25M | 5.11M | 5.58M | 23.10M | 2.48M | 3.82M | 3.84M |
| Gains from Investment Securities | -0.00M | -0.00M | 0.12M | -0.01M | -0.00M | |||||||||
| Cash from Operations | -5.24M | 40.67M | -5.38M | -10.70M | -7.97M | -8.50M | -6.17M | -10.20M | -14.41M | -15.66M | -12.20M | -13.04M | -16.27M | -11.50M |
| Depreciation, Depletion & Amortization | ||||||||||||||
| Amortizatization of Intangibles | 0.24M | 0.23M | 0.23M | 0.26M | 0.24M | 0.24M | 0.23M | 0.15M | 0.23M | 0.23M | 0.23M | 0.39M | 0.62M | 0.52M |
| Amortization of Deferred Charges | 0.03M | -0.22M | -0.00M | |||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.07M | 0.04M | 0.04M | 0.04M | 0.06M | 0.06M | 0.06M | 0.12M | 0.08M | 0.08M | 0.08M | 0.09M | 0.08M | 0.13M |
| Change in Working Capital | ||||||||||||||
| Change in Account Payables | 0.28M | -0.31M | 0.66M | -0.62M | -0.07M | 0.17M | 0.66M | 0.38M | 1.83M | -1.64M | -1.22M | 0.16M | 0.49M | -0.99M |
| Change in Accured Expenses | -0.98M | 2.15M | 2.02M | -1.60M | -0.38M | -1.46M | 1.21M | 2.94M | -2.86M | -0.10M | 0.35M | 2.10M | -3.52M | 0.77M |
| Other Working Capital Changes | -0.26M | -0.25M | 1.77M | -2.58M | -0.71M | -0.13M | -0.43M | 0.39M | -0.26M | -0.25M | 1.40M | 2.50M | 1.62M | -3.29M |
| Investing Activities | ||||||||||||||
| Capital Expenditures | 0.05M | 0.03M | 0.02M | 0.31M | 0.15M | -1.08M | -0.00M | 0.05M | 0.04M | 0.10M | 0.04M | 0.31M | 0.01M | |
| Change in Acquisitions & Divestments | 18.62M | 14.15M | 12.60M | 31.34M | 39.52M | 30.23M | 42.28M | 45.13M | 48.65M | 39.37M | 33.68M | 37.32M | 58.12M | 50.65M |
| Cash from Investing Activities | 9.36M | -44.46M | -39.50M | 9.03M | 8.73M | -38.90M | -30.18M | -9.39M | 14.91M | 13.88M | 14.94M | -47.45M | -39.31M | 4.85M |
| Financing Activities | ||||||||||||||
| Other financing activities | 0.01M | 0.02M | 0.08M | 0.05M | 0.12M | 0.01M | 0.01M | 0.26M | 0.02M | 0.24M | 0.20M | 0.20M | 0.58M | |
| Debt Issuance and Repayment | ||||||||||||||
| Long-Term Debt Repayments | 0.62M | 3.12M | ||||||||||||
| Change in Capital Stock | ||||||||||||||
| Net Shares Issued and Repurchased | 0.24M | 1.53M | 1.08M | |||||||||||
| Net Equity Issued and Repurchased | 0.31M | 19.00M | 99.20M | |||||||||||
| Misc. | ||||||||||||||
| Cash from Financing Activities | -0.62M | 46.79M | 10.32M | -0.32M | -0.02M | 108.36M | 0.01M | 0.64M | 0.02M | 0.09M | 19.11M | 93.47M | 0.13M | 1.20M |
| Change in Cash | 3.49M | 43.01M | -34.55M | -2.00M | 0.74M | 60.97M | -36.34M | -18.95M | 0.53M | -1.69M | 21.85M | 32.97M | -55.45M | -5.45M |
| Free Cash Flow | -5.30M | 40.64M | -5.40M | -11.01M | -8.12M | -7.42M | -6.17M | -10.20M | -14.46M | -15.71M | -12.29M | -13.08M | -16.58M | -11.51M |
| Net Cash Flow | 3.49M | 43.01M | -34.55M | -2.00M | 0.74M | 60.97M | -36.34M | -18.95M | 0.53M | -1.69M | 21.85M | 32.97M | -55.45M | -5.45M |